國立虎尾科技大學 |

Obesity, fatty liver and liver cancer

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Obesity, fatty liver and liver cancer/ edited by Jun Yu.
other author:	Yu, Jun.
Published:	Singapore :Springer Singapore : : 2018.,
Description:	xii, 157 p. :ill. (some col.), digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Fatty liver. -
Online resource:	http://dx.doi.org/10.1007/978-981-10-8684-7
ISBN:	9789811086847

Obesity, fatty liver and liver cancer
Obesity, fatty liver and liver cancer[electronic resource] /edited by Jun Yu. - Singapore :Springer Singapore :2018. - xii, 157 p. :ill. (some col.), digital ;24 cm. - Advances in experimental medicine and biology,v.10610065-2598 ;. - Advances in experimental medicine and biology ;780..

Chapter 1. Introduction -- Chapter 2. Epidemiology and etiology of NAFLD and associated HCC -- Chapter 3. Pathogenesis of NASH: How metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease -- Chapter 4. Chemokines and Chemokine Receptors in the Development of NAFLD -- Chapter 5. NAFLD related-HCC: the relationship with metabolic disorders -- Chapter 6. Hepatocellular carcinoma in obesity: Finding a needle in the haystack? -- Chapter 7. Dysregulated epigenetic modifications in the pathogenesis of NAFLD-HCC -- Chapter 8. The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease -- Chapter 9. Microbiota, obesity and NAFLD -- Chapter 10. Autophagy, NAFLD and NAFLD-related HCC -- Chapter 11. Animal models of non-alcoholic fatty liver diseases and its associated liver cancer -- Chapter 12. Current prevention and treatment options for NAFLD.

This volume covers a state-of-the-art illustration of recent discoveries concerning obesity-related fatty liver diseases and liver cancer. The contents are extensive and comprehensive. It brings important topics in the field all together under one umbrella, from epidemiology and etiology, molecular pathogenesis, cellular biology, epigenetics, immunology, microbiology, animal models to therapeutic approaches and treatments. All the book contributors are leading experts in the field. It will appeal to researchers, clinicians and graduate students in obesity, fatty liver diseases, GI/Liver cancer field. It may also yield benefits for pharmaceutical companies with regard to drug discovery.

ISBN: 9789811086847

Standard No.: 10.1007/978-981-10-8684-7doiSubjects--Topical Terms:

1104261
Fatty liver.

LC Class. No.: RC848.F3 / O247 2018

Dewey Class. No.: 616.362

Obesity, fatty liver and liver cancer
LDR:02737nam a2200349 a 4500 001 926855
003 DE-He213
005 20181227105949.0
006 m d
007 cr nn 008maaau
008 190626s2018 si s 0 eng d
020 $a 9789811086847 $q (electronic bk.)
020 $a 9789811086830 $q (paper)
024 7 $a 10.1007/978-981-10-8684-7 $2 doi
035 $a 978-981-10-8684-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RC848.F3 $b O247 2018
072 7 $a MBGR $2 bicssc
072 7 $a PSD $2 bicssc
072 7 $a SCI049000 $2 bisacsh
072 7 $a MED067000 $2 bisacsh
082 0 4 $a 616.362 $2 23
090 $a RC848.F3 $b O12 2018
245 0 0 $a Obesity, fatty liver and liver cancer $h [electronic resource] / $c edited by Jun Yu.
260 $a Singapore : $c 2018. $b Springer Singapore : $b Imprint: Springer,
300 $a xii, 157 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.1061
505 0 $a Chapter 1. Introduction -- Chapter 2. Epidemiology and etiology of NAFLD and associated HCC -- Chapter 3. Pathogenesis of NASH: How metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease -- Chapter 4. Chemokines and Chemokine Receptors in the Development of NAFLD -- Chapter 5. NAFLD related-HCC: the relationship with metabolic disorders -- Chapter 6. Hepatocellular carcinoma in obesity: Finding a needle in the haystack? -- Chapter 7. Dysregulated epigenetic modifications in the pathogenesis of NAFLD-HCC -- Chapter 8. The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease -- Chapter 9. Microbiota, obesity and NAFLD -- Chapter 10. Autophagy, NAFLD and NAFLD-related HCC -- Chapter 11. Animal models of non-alcoholic fatty liver diseases and its associated liver cancer -- Chapter 12. Current prevention and treatment options for NAFLD.
520 $a This volume covers a state-of-the-art illustration of recent discoveries concerning obesity-related fatty liver diseases and liver cancer. The contents are extensive and comprehensive. It brings important topics in the field all together under one umbrella, from epidemiology and etiology, molecular pathogenesis, cellular biology, epigenetics, immunology, microbiology, animal models to therapeutic approaches and treatments. All the book contributors are leading experts in the field. It will appeal to researchers, clinicians and graduate students in obesity, fatty liver diseases, GI/Liver cancer field. It may also yield benefits for pharmaceutical companies with regard to drug discovery.
650 0 $a Fatty liver. $3 1104261
650 0 $a Liver $x Cancer $x Etiology. $3 1205771
650 0 $a Obesity. $3 582756
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Molecular Medicine. $3 668353
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Hepatology. $3 673859
700 1 $a Yu, Jun. $3 972417
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v 780. $3 881230
856 4 0 $u http://dx.doi.org/10.1007/978-981-10-8684-7
950 $a Biomedical and Life Sciences (Springer-11642)